Belite Bio, Inc

NasdaqCM:BLTE Stock Report

Market Cap: US$1.7b

Belite Bio Valuation

Is BLTE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BLTE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$416.98
Fair Value
86.5% undervalued intrinsic discount
4
Number of Analysts

Below Fair Value: BLTE ($56.21) is trading below our estimate of fair value ($416.98)

Significantly Below Fair Value: BLTE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BLTE?

Key metric: As BLTE is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for BLTE. This is calculated by dividing BLTE's market cap by their current book value.
What is BLTE's PB Ratio?
PB Ratio15.5x
BookUS$112.20m
Market CapUS$1.74b

Price to Book Ratio vs Peers

How does BLTE's PB Ratio compare to its peers?

The above table shows the PB ratio for BLTE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5.9x
AMPH Amphastar Pharmaceuticals
2.4x5.8%US$1.7b
WVE Wave Life Sciences
11.8x48.8%US$1.7b
GPCR Structure Therapeutics
1.7x2.8%US$1.5b
TARS Tarsus Pharmaceuticals
7.5x54.6%US$1.8b
BLTE Belite Bio
15.5x58.5%US$1.7b

Price-To-Book vs Peers: BLTE is expensive based on its Price-To-Book Ratio (15.5x) compared to the peer average (5.9x).

Price to Book Ratio vs Industry

How does BLTE's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

19 CompaniesPrice / BookEstimated GrowthMarket Cap
RLMD Relmada Therapeutics
0.2x8.4%US$11.28m
TNFA TNF Pharmaceuticals
0.2xn/aUS$3.20m
SXTC China SXT Pharmaceuticals
0.1xn/aUS$1.43m
UPC Universe Pharmaceuticals
0.04xn/aUS$1.10m
No. of Companies22PB012345+
19 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: BLTE is expensive based on its Price-To-Book Ratio (15.5x) compared to the US Pharmaceuticals industry average (1.6x).

Price to Book Ratio vs Fair Ratio

What is BLTE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BLTE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio15.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BLTE's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BLTE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$56.21
US$79.25
+41.0%
32.9%US$110.00US$50.00n/a4
Jan ’26US$63.10
US$79.25
+25.6%
32.9%US$110.00US$50.00n/a4
Dec ’25US$63.26
US$79.25
+25.3%
32.9%US$110.00US$50.00n/a4
Nov ’25US$69.90
US$56.75
-18.8%
7.2%US$60.00US$50.00n/a4
Oct ’25US$47.26
US$56.75
+20.1%
7.2%US$60.00US$50.00n/a4
Sep ’25US$48.68
US$56.75
+16.6%
7.2%US$60.00US$50.00n/a4
Aug ’25US$48.54
US$56.50
+16.4%
6.9%US$60.00US$50.00n/a4
Jul ’25US$45.82
US$56.50
+23.3%
6.9%US$60.00US$50.00n/a4
Jun ’25US$48.95
US$56.50
+15.4%
6.9%US$60.00US$50.00n/a4
May ’25US$41.02
US$56.50
+37.7%
6.9%US$60.00US$50.00n/a4
Apr ’25US$36.91
US$56.50
+53.1%
6.9%US$60.00US$50.00n/a4
Mar ’25US$46.52
US$56.50
+21.5%
6.9%US$60.00US$50.00n/a4
Feb ’25US$45.11
US$56.50
+25.2%
6.9%US$60.00US$50.00n/a4
Jan ’25US$45.75
US$55.25
+20.8%
10.9%US$60.00US$45.00US$63.104
Dec ’24US$42.12
US$53.67
+27.4%
11.5%US$59.00US$45.00US$63.263
Nov ’24US$39.40
US$45.00
+14.2%
28.3%US$57.00US$25.00US$69.904
Oct ’24US$31.85
US$45.00
+41.3%
28.3%US$57.00US$25.00US$47.264
Sep ’24US$33.00
US$45.00
+36.4%
28.3%US$57.00US$25.00US$48.684
Aug ’24US$21.81
US$45.00
+106.3%
28.3%US$57.00US$25.00US$48.544
Jul ’24US$14.29
US$56.00
+291.9%
1.8%US$57.00US$55.00US$45.822
Jun ’24US$17.02
US$57.50
+237.8%
0.9%US$58.00US$57.00US$48.952
May ’24US$28.80
US$57.50
+99.7%
0.9%US$58.00US$57.00US$41.022
Apr ’24US$29.90
US$57.50
+92.3%
0.9%US$58.00US$57.00US$36.912
Mar ’24US$33.33
US$57.50
+72.5%
0.9%US$58.00US$57.00US$46.522
Feb ’24US$29.61
US$57.50
+94.2%
0.9%US$58.00US$57.00US$45.112
Jan ’24US$30.15
US$57.50
+90.7%
0.9%US$58.00US$57.00US$45.752
Analyst Price Target
Consensus Narrative from 4 Analysts
US$79.25
Fair Value
29.1% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 11:51
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Belite Bio, Inc is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruce JacksonBenchmark Company
Jennifer KimCantor Fitzgerald & Co.
Yi ChenH.C. Wainwright & Co.